Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Coronavirus Vaccine - iBio/Beijing CC Pharming

Drug Profile

Coronavirus Vaccine - iBio/Beijing CC Pharming

Alternative Names: Coronavirus vaccine - CC Pharming; Coronavirus Vaccine - iBio; IBIO-200; SARS-CoV-2 virus like particle vaccine-iBio

Latest Information Update: 15 Apr 2020

At a glance

  • Originator Beijing CC-Pharming; iBio Inc
  • Developer Beijing CC-Pharming; iBio Inc; Texas A&M University
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical COVID 2019 infections

Most Recent Events

  • 09 Apr 2020 iBio signs a Memorandum of Understanding with the Infectious Disease Research Institute for IBIO 200
  • 26 Mar 2020 Preclinical trials in COVID-2019 infections in USA (unspecified route)
  • 26 Mar 2020 iBio plans clinical development for COVID-2019 infections

Development Overview

Introduction

Plant based coronavirus vaccine is being developed by iBio and Beijing CC Pharming using iBio's FastPharming System™ for the treatment of COVID-2019 infections. FastPharming System™ combines vertical farming, automated hydroponics, and glycan engineering technologies wherein plants are used as bioreactors for development of vaccines and biologics. Preclinical development is underway in the US. Early research is underway in China.

Company Agreements

In April 2020,iBio signed a Memorandum of Understanding (MOU) with the Infectious Disease Research Institute (IDRI) to support iBio’s SARS-CoV-2 Virus-Like Particle (VLP) vaccine development. The MOU calls for iBio and IDRI to establish a separate, additional agreement within the next 60 days if iBio opts to include one of IDRI’s adjuvants in the COVID-19 vaccine development programme (IBIO 200). The MoU integrates IDRI into iBio’s collaboration with the Texas A&M University System to create a strong partnership that brings deep experience and advanced technologies and capabilities to the task of moving IBIO 200 into the clinic. [1]

In June 2016, Texas A&M University System entered into a development agreement with iBio for collaborative program in plant-produced pharmaceuticals. The collaboration will use the research and development resources of TAMUS with the commercial therapeutics and vaccine development and manufacturing capabilities of iBio. [2]

Key Development Milestones

In March 2020, iBio initiated preclinical studies of IBIO 200 at the Texas A&M University System (“TAMUS”) laboratories as part of the Master Joint Development Agreement established between iBio and TAMUS [3] .

As of February 2020, plant based coronavirus vaccine is in early research for the treatment of COVID-2019 infections [4] .

Drug Properties & Chemical Synopsis

  • Formulation Injection
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • WHO ATC code

    J07B-X (Other viral vaccines)

  • EPhMRA code

    J7A9 (Other specified single component)

Development Status

Summary Table

Indication Qualifier Patient Segment Phase Countries Route / Formulation Developers Event Date
COVID 2019 infections - - Preclinical USA unspecified / Injection iBio Inc, Texas A&M University 26 Mar 2020
COVID 2019 infections - - Research China unspecified / Injection Beijing CC-Pharming, iBio Inc 06 Feb 2020

Commercial Information

Involved Organisations

Organisation Involvement Countries
Beijing CC-Pharming Originator China
iBio Inc Originator USA
iBio Inc Owner USA
Beijing CC-Pharming Owner China
Texas A&M University Collaborator USA
Infectious Disease Research Institute Collaborator USA

Development History

Event Date Update Type Comment
09 Apr 2020 Licensing Status iBio signs a Memorandum of Understanding with the Infectious Disease Research Institute for IBIO 200 [1] Updated 15 Apr 2020
26 Mar 2020 Phase Change - Preclinical Preclinical trials in COVID-2019 infections in USA (unspecified route) [3] Updated 01 Apr 2020
26 Mar 2020 Trial Update iBio plans clinical development for COVID-2019 infections [3] Updated 01 Apr 2020
11 Feb 2020 Phase Change Early research in COVID-2019-infections in USA (unspecified route) Updated 11 Feb 2020
06 Feb 2020 Phase Change Early research in COVID-2019-infections in China (unspecified route) [4] Updated 11 Feb 2020
13 Jun 2016 Licensing Status iBio and Texas A&M University agree co-develop vaccines [2] Updated 01 Apr 2020

References

  1. iBio Expands COVID-19 Vaccine Collaboration to Include the Infectious Disease Research Institute.

    Media Release
  2. Texas A&M University System and iBio Execute Joint Development Agreement for Plant-Produced Pharmaceuticals.

    Media Release
  3. iBio Announces Advancement of COVID-19 Vaccine Program.

    Media Release
  4. iBio and CC-Pharming Initiate Joint Development of Coronavirus Vaccine.

    Media Release
Back to top